Jeffrey Parnell, MD
Retina Specialist · Chicago, ILNPI 1902873722
Payments from drug & device makers
What this record shows
This record is dominated by ownership interests: $26,365 of the $26,895 with a category attached, or 98.0%. US Retina LLC accounts for 98.0% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2021 at $10,412 and has fallen 98.1% since, to $200 in 2025.
Across 26 payments — averaging $1034.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- US Retina LLC$26K
- Apellis Pharmaceuticals, Inc.$168
- Regeneron Healthcare Solutions, Inc.$146
- Genentech USA, Inc.$74
- Astellas Pharma US Inc$45
- AbbVie$24
- plus $72 from 4 others
What the payments were for
- Food & beverage$5302%
- Ownership interest$26,36598%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| US Retina LLC | 6 | $26,365 |
| Apellis Pharmaceuticals, Inc. | 6 | $168 |
| Regeneron Healthcare Solutions, Inc. | 4 | $146 |
| Genentech USA, Inc. | 3 | $74 |
| Astellas Pharma US Inc | 2 | $45 |
| AbbVie | 1 | $24 |
| Biogen | 1 | $21 |
| Novartis | 1 | $21 |
| Vyera Pharmaceuticals, LLC | 1 | $19 |
| Optos, Inc. | 1 | $11 |
How this compares
$26,895 in reported general payments places this provider in the 80th percentile of 70 retina specialist providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 12 | $1,311 |
| Prednisolone Acetate | 47 | $1,278 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 12 | $398 |
| Latanoprost | 28 | $338 |
| Timolol Maleate | 42 | $265 |
| Ketorolac Tromethamine | 14 | $151 |
| Brimonidine Tartrate | 11 | $147 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Chicago
- Rahul KomatiChicago$143K
- Veena RaijiChicago$69K
- Paulpoj ChiranandChicago$17K
- Henry FengChicago$16K
- Shaun IttiaraChicago$9K
- Sarah SyedaChicago$6K
- Saagar PanditChicago$6K
- Daniel BalikovChicago$3K
- Emily ShepherdChicago$3K
- John WilguckiChicago$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.